Pharmacyte Biotech, Inc. (PMCB) — SEC Filings
Pharmacyte Biotech, Inc. (PMCB) — 24 SEC filings. Latest: 10-Q (Dec 18, 2025). Includes 8 8-K, 6 10-Q, 3 DEF 14A.
View Pharmacyte Biotech, Inc. on SEC EDGAR
Overview
Pharmacyte Biotech, Inc. (PMCB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Dec 18, 2025: PharmaCyte Biotech, Inc. (PMCB) reported a significant net loss of $15,778,071 for the six months ended October 31, 2025, a stark contrast to the net income of $21,951,795 in the prior year period. This substantial loss was primarily driven by a $10,231,000 negative change in the fair value of warra
Sentiment Summary
Across 24 filings, the sentiment breakdown is: 5 bearish, 19 neutral. The dominant filing sentiment for Pharmacyte Biotech, Inc. is neutral.
Filing Type Overview
Pharmacyte Biotech, Inc. (PMCB) has filed 6 10-Q, 8 8-K, 1 8-K/A, 3 DEF 14A, 2 10-K, 2 SC 13G/A, 1 SC 13D, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (24)
Risk Profile
Risk Assessment: Of PMCB's 20 recent filings, 5 were flagged as high-risk, 9 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | ($15,778,071) |
| EPS | ($2.47) |
| Debt-to-Equity | 0.55 |
| Cash Position | $15,406,017 |
| Operating Margin | N/A |
| Total Assets | $55,976,469 |
| Total Debt | $19,422,384 |
Key Executives
- Joshua Silverman
Industry Context
The biotechnology sector, particularly in oncology, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like PharmaCyte face intense competition and the need for substantial capital to advance drug candidates through clinical trials. Success is often dependent on achieving regulatory approval and demonstrating clinical efficacy, with many early-stage companies relying on partnerships or significant funding rounds.
Top Tags
biotech (6) · Biotechnology (4) · 10-Q (4) · corporate-governance (3) · shareholder-vote (3) · financials (3) · FDA Clinical Hold (2) · Net Loss (2) · Strategic Review (2) · amendment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $15.8M | For the six months ended October 31, 2025, a significant swing from prior year's net income. |
| Change in Fair Value of Warrant Liability | $10.2M | A major contributor to the net loss for the six months ended October 31, 2025. |
| Change in Fair Value of Investment - QCLS | $5.2M | Another significant factor in the reported net loss for the six months ended October 31, 2025. |
| Net Proceeds from Series C Preferred Stock | $6.2M | Helped increase cash and cash equivalents despite operating losses. |
| Cash and Cash Equivalents | $15.4M | As of October 31, 2025, showing a slight increase from April 30, 2025. |
| Total Operating Expenses | $2.2M | For the six months ended October 31, 2025, a slight decrease from the prior year. |
| Basic and Diluted Loss Per Share | $1.24 | For the three months ended October 31, 2025, indicating increased losses per share. |
| Shares of Series C convertible preferred stock | 7,000 | Initially convertible into up to 7,000,000 shares of Common Stock |
| Shares of Common Stock | 7,000,000 | Underlying warrants issued in private placement |
| Shares | 2,250,000 | Increase in shares available for the 2022 Equity Incentive Plan |
| Percentage of outstanding common stock | 20% | Threshold for Nasdaq Listing Rule 5635(d) requiring stockholder approval for issuance |
| Shares of Common Stock outstanding | 6,795,779 | Entitled to vote on the Record Date |
| Aggregate votes from Series C Preferred Stock | 930,836 | On an as-converted basis for Proposals 2 and 3 |
| Total Other Income (Loss), Net | $7,511,791 | a loss for the three months ended July 31, 2025, compared to a gain of $24,690,242 in 2024 |
| Gain on Related Party Investment - TNF | $21,395,734 | recorded in 2024 but not in 2025, significantly impacting net income |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Pharmacyte Biotech, Inc. (PMCB)?
Pharmacyte Biotech, Inc. has 24 recent SEC filings from Feb 2024 to Dec 2025, including 8 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PMCB filings?
Across 24 filings, the sentiment breakdown is: 5 bearish, 19 neutral. The dominant sentiment is neutral.
Where can I find Pharmacyte Biotech, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pharmacyte Biotech, Inc. (PMCB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pharmacyte Biotech, Inc.?
Key financial highlights from Pharmacyte Biotech, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PMCB?
The investment thesis for PMCB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pharmacyte Biotech, Inc.?
Key executives identified across Pharmacyte Biotech, Inc.'s filings include Joshua Silverman.
What are the main risk factors for Pharmacyte Biotech, Inc. stock?
Of PMCB's 20 assessed filings, 5 were flagged high-risk, 9 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Pharmacyte Biotech, Inc.?
Forward guidance and predictions for Pharmacyte Biotech, Inc. are extracted from SEC filings as they are enriched.